Zymic Technology (ZYMIQ) Q3 2025 earnings summary

Executive summary

• Achieved significant international expansion through new strategic partnerships and distribution agreements in Asia and Europe, strengthening the foundation for future growth.

• Relocated production of key products to Sweden, achieving targeted cost levels and improved quality control.

• Scientific breakthroughs in enzyme technology for both human and animal health, with in-vivo studies confirming efficacy against multidrug-resistant bacteria.

Financial highlights

• Net sales for Jan–Sep 2025 increased by 53% year-over-year to SEK 1,546 thousand (1,012).

• Q3 2025 net sales were SEK 400 thousand, up from SEK 268 thousand in Q3 2024.

• Loss after tax for Jan–Sep 2025 was SEK -6,242 thousand, an improvement from SEK -8,343 thousand year-over-year.

• Q3 2025 loss after tax was SEK -1,030 thousand, compared to SEK -3,008 thousand in Q3 2024.

• Cash and cash equivalents at period end were SEK 1,960 thousand, up from SEK 1,018 thousand year-over-year.

Outlook and guidance

• Business model is ready to scale globally, with new distribution agreements and production relocation supporting long-term growth into 2026.

• Focus on launching new products and expanding international presence, especially in Asia.